chimera bioengineering logo

Chimera Bioengineering

Chimera Bioengineering is a biotherapeutics company building RNA based gene regulatory systems for chimeric antigen receptor CAR-T cell therapeutics with greater efficacy against solid tumors and superior safety.

Chimera was co-founded by synthetic biologist, Prof. Christina Smolke, of Stanford University, and leverages the combination of synthetic biology and immunotherapy, to widen therapeutic windows against cancer. Chimera is a resident at JLABS incubator in South San Francisco and has the support of StartX, the Stanford affiliated accelerator and Illumina Accelerator.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttp://www.driverb.io
Founded2015
Disease Focus
Development Stage
STOCK CODENon Listed
Address
499 Illinois Street.San Francisco, CA 94158.
San Francisco
United States
Email
Contact Number
+1 310 497-0736

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/chimera-bioengineering” connections=”true” suffix=””]

Chimera builds engineered CAR T cell therapeutics using synthetic biology and rewire immuno-metabolic gene regulation to augment CAR potency, prevent runaway toxicity and develop a wholly new class of drug targets.

In 2017, Chimera Bioengineering received undisclosed venture funding from Kairos Ventures to advance Chimeras technology platforms and CAR-T therapeutics product programs.